Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Jul 14 · inside the Ichimoku cloud · RSI 98 (overbought) · MACD below its signal
None of the 29 investors followed here reported a position in NMTRQ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NMTRQ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NMTRQ.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 400.0 | -98.0 | 0.0 | 0.0 | 0.0 | 900.0 | 0.0 | 0.0 | 0.0 | −0.0% | ||
| 2025 | 900.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +900.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | −90.0% |
| 2023 | 60.3 | -15.8 | -18.2 | -37.4 | -19.5 | -4.0 | -96.3 | -56.0 | 9.1 | -90.8 | -90.9 | 0.0 | −100.0% |
| 2022 | -22.0 | -28.5 | 9.8 | -30.3 | 8.2 | -42.3 | -15.6 | 20.4 | -18.9 | -40.2 | -33.5 | -26.3 | −93.6% |
| 2021 | 61.8 | 19.4 | -29.5 | 4.3 | 4.9 | -14.1 | -1.8 | 20.4 | 0.0 | -2.3 | -18.1 | -5.9 | +13.9% |
| 2020 | 34.6 | -25.3 | -10.1 | 39.5 | -19.5 | 1.4 | -17.0 | 37.1 | 25.0 | -20.2 | 49.4 | -11.6 | +54.2% |
| 2019 | 1.7 | -11.5 | -7.2 | -16.6 | -20.5 | -9.4 | -9.5 | -17.6 | 23.7 | -24.3 | -3.7 | -28.6 | −75.9% |
| 2018 | -4.9 | -9.3 | 420.5 | -36.3 | -24.7 | 79.4 | -77.9 | 36.4 | -4.1 | -38.4 | -38.2 | -11.2 | −62.1% |
| 2017 | -8.0 | -9.9 | -17.2 | -15.8 | -43.6 | -14.4 | 31.1 | 22.8 | -11.0 | -18.9 | 18.1 | -9.0 | −65.1% |
| 2016 | -21.2 | -35.8 | -19.8 | 9.0 | 19.9 | −47.0% |
No analyst coverage for this instrument.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
No recent headlines.